Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-1-4
pubmed:abstractText
All current seroassays using cultured Borrelia burgdorferi as their antigen source have been rendered obsolete by the recombinant OspA Lyme disease vaccine. OspA is the major outer surface protein expressed in cultured B. burgdorferi, and any seroassay that uses whole organisms as its antigen source cannot differentiate between subjects who received the vaccine and those who were naturally infected. We developed a new sensitive and specific enzyme-linked immunosorbent assay (ELISA) utilizing recombinant chimeric borrelia proteins devoid of OspA (rNon-OspA) that can be used to detect antibodies to diagnostically important B. burgdorferi antigens in both OspA-vaccinated and nonvaccinated individuals. We tested sera from patients with Lyme disease and with conditions associated with false-positive serologies, OspA-vaccinated individuals, and healthy high-risk workers from an area of endemicity and normal sera from individuals from areas of nonendemicity. The rNon-OspA test was compared with two commercially available whole-cell immunoassays. The rNon-OspA assay is as sensitive and specific as the whole-cell assay (P > 0.05) for detection of anti-B. burgdorferi antibodies. However, the rNon-OspA assay can differentiate between populations comprised of naturally infected and OspA-vaccinated individuals (P < 0.05). Our data demonstrate that this new sensitive rNon-OspA ELISA can be used for the laboratory detection of B. burgdorferi antibodies regardless of vaccination status and could replace existing serologic assays for Lyme disease.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10377134, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10523583, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10565920, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10565921, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10618107, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10790090, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-10878038, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-11139199, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-11525704, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-2199796, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-2295795, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-2668764, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-7591099, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-8221523, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-8283961, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-8862103, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-8887347, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-9108482, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-9399504, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-9542898, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-9673298, http://linkedlifedata.com/resource/pubmed/commentcorrection/11773115-9717677
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0095-1137
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
193-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status.
pubmed:affiliation
Brook Biotechnologies, Inc., Stony Brook, New York 11790-3350, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Evaluation Studies